OncoAlert

🚨 Oncología Ahora y en Directo | Avances en Cáncer de Vejiga Avanzado 

En este episodio, las Dras. @nataliagandur 🇦🇷 y @ReginaBarCar 🇲🇽 analizan los avances más recientes en el tratamiento del carcinoma urotelial localmente avanzado y metastásico, destacando el impacto transformador de la inmunoterapia perioperatoria y las combinaciones con anticuerpos conjugados (ADCs).

👉 Basado en estudios clave como NIAGARA, EV-301, EV-302 y CheckMate 901, el episodio explora cómo estas estrategias están redefiniendo los estándares internacionales en #BladderCancer.

💡 Las expertas también discuten los desafíos de acceso y equidad en América Latina, donde las barreras estructurales y regulatorias dificultan la implementación de terapias innovadoras.

🌎 Con una mirada crítica y comprometida, las Dras. Gandur y BarCar resaltan la importancia de adaptar las guías globales a entornos con recursos limitados, impulsar la participación en ensayos clínicos regionales, y promover consensos locales que reflejen la realidad de nuestros pacientes.

🎯 Conclusión: La oncología debe ser un derecho universal, no un privilegio.

📲 Suscríbete a OncoAlert360 para no perderte los próximos episodios de Oncología Ahora y en Directo con líderes en investigación y práctica clínica.

🎙️ Oncology Here & Now Podcast | Season 2, Episode 3

In this episode, we explore HER2-positive advanced breast cancer with a leading experts in the field Dr. Elisa Agostinetto and Dr. Erika Hamilton. We discuss the evolving treatment landscape, including first-line standards like the CLEOPATRA regimen and the latest DestinyBreast09 results from ASCO, and practical strategies for patient selection and toxicity management in daily clinical practice.
Key topics covered in this episode:

– Current standard of care for HER2+ ABC
– Impact of DestinyBreast09 results: Should T-DXd + pertuzumab be used for all patients or select patients?
 – Optimal treatment duration: induction vs maintenance strategies
– Monitoring ILD: CT scan frequency and best practices
– T-DXd rechallenge after grade 1 ILD: real-world insights

This episode is a must-listen for oncologists, hematologists, and healthcare professionals seeking practical guidance to improve patient care in HER2+ advanced breast cancer.

🔔 Subscribe for weekly episodes and stay updated on the latest in oncology

Join Dr. Gil Morgan in conversation with Mr. Tyler Kratzer of the American Cancer Society, lead author of Prostate Cancer Statistics 2025 (published in CA: A Cancer Journal for Clinicians).

📖 Read the paper here: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.70028

Key Insights:
⚠️ Racial disparities persist:
Black men: 2× higher mortality & 67% higher incidence
American Indian/Alaska Native men: 12% higher mortality despite lower incidence
Asian American/Pacific Islander & Hispanic men: less often diagnosed with localized disease
👉 Take-home message: Rising rates of advanced prostate cancer and persistent disparities underscore the urgent need to improve early detection strategies, avoid overdiagnosis, and address inequities in outcomes.

The OncoAlert Weekly Roundup is your go-to podcast for the latest, most impactful updates in oncology from across the globe 🌍. Each week, we break down the key studies shaping cancer care—so you stay ahead, in just minutes.

This week’s highlights include:
🔹 PRIME Diagnostic Trial: Bi-MRI vs. mp-MRI in #ProstateCancer
🔹 NECTIN4-CAR T cells show promise in #BladderCancer
🔹 Global consensus on bladder-sparing MIBC trial endpoints
🔹 PREOPANC-2 in resectable #PancreaticCancer
🔹 WU-KONG1B: Sunvozertinib in EGFR exon20 #NSCLC
🔹 Updated ASTRO–ASCO–SSO guideline on PMRT in #BreastCancer
🔹 Impact of sequential ADCs in HER2- MBC
🔹 Sacituzumab govitecan in low-grade serous #OvarianCancer
🔹 OlAnCa Trial: Olanzapine in cancer cachexia
🔹 Nurse-delivered Meaning-Centered Psychotherapy for advanced cancer

👉 Don’t miss an episode—subscribe now for concise, evidence-based insights that matter to your practice.
✨ Stay tuned. Stay informed. Stay #OncoAlert.

El nuevo podcast de OncoAlert 🚨 en nuestro idioma! Con nuestras colegas Dra. Natalia Gandur (Argentina) y Dra. Reginia Barragán (México).

En este primer episodio, las doctoras Barragán-Carrillo y Gandur nos cuentan qué esperar de este webcast enfocado en el tratamiento del cáncer en LATAM y mucho más!

🎧 Disponible aquí y como podcast. ¡Cordialmente invitados!
Temporada 1 Episodio 1

This week on The OncoAlert Weekly Round Up, we spotlight precision oncology in action with top-tier studies making headlines:

🧬 Biomarkers in Breast Cancer Immunotherapy
We break down a critical review by Li et al. and Sherene Loi in The Breast on the evolving biomarker landscape for immune checkpoint inhibitors (ICIs) in breast cancer. PD-L1 isn’t enough—so what’s next? TILs, HRD, TMB, and even signals in luminal tumors might hold the key.

🧪 ER+/HER2+ Subtype Shifts with Preop Endocrine Therapy
A translational analysis from the POETIC trial shows how 2 weeks of aromatase inhibitors can flip high-risk luminal B tumors into luminal A—and change everything about treatment decisions.

🧠 Metabolic Warfare in Brain Metastases
From Nature Reviews Cancer, we explore how cancer cells rewire their metabolism to colonize the brain—and why targeting those pathways could change the game.

🚭 Platinum-Ineligible NSCLC: Real-World Wins for Atezolizumab
Post hoc analysis from IPSOS reinforces immunotherapy’s role for frail lung cancer patients previously excluded from platinum therapy.

🔬 Targeting BRAF in NSCLC: Real-World Outcomes from Turkey
Data from the Turkish Oncology Group reveal the strengths—and survival gaps—of D+T versus chemo, especially in the presence of co-mutations.

💥 Pancreatic Cancer Regimens Face Off in GENERATE Trial
A surprise outcome from JCOG1611 as nab-paclitaxel + gemcitabine outpaces mFOLFIRINOX and S-IROX—raising new questions for front-line care.

🧻 Total Neoadjuvant Therapy in Rectal Cancer: Global Perspective
An international analysis confirms that multiple TNT regimens are working in practice—offering real hope in high-risk stage II/III disease.

⚡ Sequencing Matters in mCRPC
New data suggest enzalutamide before 177Lu-PSMA-617 yields better outcomes than abiraterone—highlighting the power of strategic sequencing.

💸 The Hidden Economic Toll on Cancer Caregivers
A sobering study from Australia puts numbers behind the emotional and financial costs borne by informal cancer caregivers—and calls for policy reform.

🚨 Don’t miss this high-impact episode packed with clinical insights, translational breakthroughs, and real-world data that matter for your daily practice.

📲 Stream now on your favorite podcast app

Welcome to another impactful episode of The OncoAlert Weekly Roundup — your go-to source for the latest breakthroughs in oncology, hosted by Gil Morgan.

🚨 This week, we’re diving deep into where precision meets practicality — from genomic tools redefining risk in breast and lung cancer, to combination therapies setting new standards, and even exercise as a tool in metastatic prostate cancer.

🧬 Highlights include:

• Groundbreaking data on HER2DX and ctDNA in early-stage cancer
• Long-term FLAURA2 results showing improved survival in EGFR-mutant NSCLC
• A compelling review on the anti-cancer potential of exercise in advanced prostate cancer
• The science behind epithelial–mesenchymal transition (EMT) and why it matters now more than ever

💡 Whether you're a clinician, researcher, or cancer care advocate, this week’s roundup gives you the insights you need to stay ahead in the rapidly evolving world of oncology.

👇 Don’t forget:
✅ Subscribe for weekly updates
📬 Sign up for our newsletter: www.oncoalert360.com
📢 Share with colleagues & join the conversation in the comments
🔔 Hit the bell so you never miss an update

From game-changing trial results to the evolving science behind personalized cancer care, this week’s OncoAlert Round Up dives into the most impactful studies shaking up the oncology landscape. We explore the TALAPRO-2 trial’s final analysis showing that talazoparib plus enzalutamide significantly improves survival in men with HRR-deficient mCRPC—especially those with BRCA1/2 alterations—positioning it as a potential new standard of care. Plus, we unpack new insights into geriatric assessment in oncology, breastfeeding post–HR+ breast cancer (POSITIVE trial), non-clear cell RCC, brain metastases at single-cell resolution, MMR-deficient cancer treatment, microbiome modulation, and more. Whether you're a clinician, researcher, or just passionate about cancer science, this episode delivers everything you need to stay ahead.

Listen now and subscribe for your weekly dose of cutting-edge cancer care.

The OncoAlert🚨ROUND UP  Now Out‼️
 Covering May 15-22, 2025 

REGISTER at http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/...

⭐️Discussing
✅Systemic tx for HR+/HER2- early stage and metastatic #BreastCancer
✅Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized #ProstateCancer
✅Characterization of Patients with Lymph Node Only Metastatic #UrothelialCarcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial
✅NO LIMIT Study: in Advanced Gastric or Esophagogastric Junction Cancer
✅PRODIGE 29-UCGI 26 (NEOPAN)on #PancreaticCarcinoma
and more.....

Join our Urology colleagues, Dr. Melao and Dr. Spiess, as they discuss upper tract urothelial carcinoma—from risk stratification to management strategies in both low-risk and high-risk, high-grade settings. They’ll also explore long-term renal function outcomes, a topic on which Dr. Spiess has recently published.